Metrics as of 10/16/2026, 07:49 AM (Berlin time), refresh in progress.
Dyadic International Stock
Dyadic International, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark A. Emalfarb
- Employees
- 5
- Market cap
- $17 M
- IPO
- 16/01/2008
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological…
Dyadic International stock: price history
1D
+2.2%
1W
-5.6%
1M
-2.0%
6M
-52.2%
YTD
-55.4%
1Y
-59.3%
2Y
-61.2%
5Y
-91.4%
10Y
-74.3%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~18% weaker price swings than usual
Ask the agents about Dyadic International
Analyst assessment of Dyadic International
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 14/11/2024
Dyadic International stock metrics
P/E
-1.97
P/B
-6.4
EV/EBITDA
-2.84
RETURN ON EQUITY
89.0%
NET MARGIN
-221.0%
DEBT/EQUITY
-2.11
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.6%
FLOAT SHARES
27,495,552
AVG. DAILY VOLUME (30D)
178,894
Insider transactions (SEC)
Francisco Trust under agreement dated February 28, 1996
Francisco Trust under agreement dated February 28, 1996
Francisco Trust under agreement dated February 28, 1996
Francisco Trust under agreement dated February 28, 1996
Francisco Trust under agreement dated February 28, 1996
Institutional holders
Comparable stocks
Frequently asked questions about Dyadic International stock
What does Dyadic International do?
Dyadic International, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark A. Emalfarb, the company employs around 5 people.
The IPO was on 16/01/2008; the stock trades on NASDAQ under the ticker DYAI.
What do analysts say about Dyadic International stock?
2 analysts rate the stock, the consensus is Buy (as of 14/11/2024).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Dyadic International report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -18% stronger than usual.
Does Dyadic International pay a dividend?
No, Dyadic International currently does not pay a dividend.
Which stocks are comparable to Dyadic International?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Dyadic International stock analyzed?
Clicking "Analyze stock" lets five strategies assess Dyadic International against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.